{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:36:47Z","timestamp":1773970607083,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40744-020-00269-6","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T13:02:43Z","timestamp":1608642163000},"page":"273-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies"],"prefix":"10.1007","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct01358175","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01863732","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01649375","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xenofon","family":"Baraliakos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro M.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianne S.","family":"Gensler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bintu","family":"Sherif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erhard","family":"Quebe-Fehling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corine","family":"Gaillez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"issue":"9570","key":"269_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379\u201390.","journal-title":"Lancet"},{"issue":"9783","key":"269_CR2","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","volume":"377","author":"M Dougados","year":"2011","unstructured":"Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377(9783):2127\u201337.","journal-title":"Lancet"},{"issue":"6","key":"269_CR3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3111\/13696998.2012.692341","volume":"15","author":"X Gao","year":"2012","unstructured":"Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. J Med Econ. 2012;15(6):1054\u201363.","journal-title":"J Med Econ"},{"issue":"1","key":"269_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"269_CR5","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1136\/annrheumdis-2016-209209","volume":"75","author":"D Poddubnyy","year":"2016","unstructured":"Poddubnyy D, Protopopov M, Haibel H, Braun J, Rudwaleit M, Sieper J. High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Ann Rheum Dis. 2016;75(12):2114\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"269_CR6","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","volume":"73","author":"S Ramiro","year":"2014","unstructured":"Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014;73(8):1455\u201361.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"269_CR7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3899\/jrheum.170222","volume":"45","author":"X Baraliakos","year":"2018","unstructured":"Baraliakos X, Berenbaum F, Favalli EG, et al. Challenges and advances in targeting remission in axial spondyloarthritis. J Rheumatol. 2018;45(2):153\u20137.","journal-title":"J Rheumatol"},{"issue":"6","key":"269_CR8","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"269_CR9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/annrheumdis-2013-203860","volume":"73","author":"MM Schoels","year":"2014","unstructured":"Schoels MM, Braun J, Dougados M, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014;73(1):238\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"269_CR10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1517\/14712598.2016.1167183","volume":"16","author":"J Braun","year":"2016","unstructured":"Braun J, Baraliakos X, Kiltz U. Secukinumab (AIN457) in the treatment of ankylosing spondylitis. Expert Opin Biol Ther. 2016;16(5):711\u201322.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"269_CR11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/BOR.0000000000000301","volume":"28","author":"A Paine","year":"2016","unstructured":"Paine A, Ritchlin CT. Targeting the interleukin-23\/17 axis in axial spondyloarthritis. Curr Opin Rheumatol. 2016;28(4):359\u201367.","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"269_CR12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/acr.22708","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res. 2016;68(2):151\u201366.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"269_CR13","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/ar4244","volume":"15","author":"X Baraliakos","year":"2013","unstructured":"Baraliakos X, Haibel H, Fritz C, et al. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther. 2013;15(3):R67.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"269_CR14","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","volume":"50","author":"X Baraliakos","year":"2011","unstructured":"Baraliakos X, Listing J, Fritz C, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years\u2013early clinical response predicts long-term outcome. Rheumatology (Oxford). 2011;50(9):1690\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"269_CR15","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896\u2013904.","journal-title":"Ann Rheum Dis"},{"issue":"9906","key":"269_CR16","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705\u201313.","journal-title":"Lancet"},{"issue":"26","key":"269_CR17","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"269_CR18","first-page":"50","volume":"36","author":"X Baraliakos","year":"2018","unstructured":"Baraliakos X, Kivitz AJ, Deodhar AA, et al. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol. 2018;36(1):50\u20135.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"269_CR19","doi-asserted-by":"crossref","first-page":"e000592","DOI":"10.1136\/rmdopen-2017-000592","volume":"3","author":"H Marzo-Ortega","year":"2017","unstructured":"Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. RMD Open. 2017;3(2):e000592.","journal-title":"RMD Open"},{"issue":"7","key":"269_CR20","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/acr.23233","volume":"69","author":"H Marzo-Ortega","year":"2017","unstructured":"Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study. Arthritis Care Res. 2017;69(7):1020\u20139.","journal-title":"Arthritis Care Res"},{"issue":"6","key":"269_CR21","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J Braun","year":"2017","unstructured":"Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76(6):1070\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"269_CR22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/rheumatology\/key375","volume":"58","author":"J Braun","year":"2019","unstructured":"Braun J, Baraliakos X, Deodhar A, et al. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology (Oxford). 2019;58(5):859\u201368.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"269_CR23","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361\u20138.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"269_CR24","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286\u201391.","journal-title":"J Rheumatol"},{"issue":"20","key":"269_CR25","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","unstructured":"World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"issue":"1","key":"269_CR26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landewe R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70(1):47\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"269_CR27","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):ii1-44.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"269_CR28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/rheumatology\/keh549","volume":"44","author":"KL Haywood","year":"2005","unstructured":"Haywood KL, Garratt AM, Dawes PT. Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatology (Oxford). 2005;44(5):577\u201386.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"269_CR29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.62.1.20","volume":"62","author":"L Doward","year":"2003","unstructured":"Doward L, Spoorenberg A, Cook SA, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 2003;62(1):20\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"269_CR30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13(2):63\u201374.","journal-title":"J Pain Symptom Manage"},{"issue":"24","key":"269_CR31","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","volume":"25","author":"JE Ware Jr","year":"2000","unstructured":"Ware JE Jr. SF-36 health survey update. Spine. 2000;25(24):3130\u20139.","journal-title":"Spine"},{"issue":"4","key":"269_CR32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/01.jom.0000063619.37065.e2","volume":"45","author":"R Loeppke","year":"2003","unstructured":"Loeppke R, Hymel PA, Lofland JH, et al. Health-related workplace productivity measurement: general and migraine-specific recommendations from the ACOEM Expert Panel. J Occup Environ Med. 2003;45(4):349\u201359.","journal-title":"J Occup Environ Med"},{"issue":"10","key":"269_CR33","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","volume":"77","author":"PM Machado","year":"2018","unstructured":"Machado PM, Landewe R, Heijde DV, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018;77(10):1539\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"269_CR34","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3899\/jrheum.111337","volume":"39","author":"J Paccou","year":"2012","unstructured":"Paccou J, Bacle-Boutry MA, Solau-Gervais E, Bele-Philippe P, Flipo R-M. Dosage adjustment of anti-tumor necrosis factor-alpha inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice. J Rheumatol. 2012;39(7):1418\u201323.","journal-title":"J Rheumatol"},{"issue":"8","key":"269_CR35","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","volume":"44","author":"JJ Anderson","year":"2001","unstructured":"Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44(8):1876\u201386.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"269_CR36","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/art.21588","volume":"53","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Brandt J, Listing J, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum. 2005;53(6):856\u201363.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"269_CR37","first-page":"174","volume":"33","author":"S Arends","year":"2015","unstructured":"Arends S, van der Veer E, Kamps FB, et al. Patient-tailored dose reduction of TNF-alpha blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin Exp Rheumatol. 2015;33(2):174\u201380.","journal-title":"Clin Exp Rheumatol"},{"issue":"9313","key":"269_CR38","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359(9313):1187\u201393.","journal-title":"Lancet"},{"issue":"11","key":"269_CR39","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230\u20136.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"269_CR40","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58(11):3402\u201312.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"269_CR41","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582\u201391.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"269_CR42","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136\u201346.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"269_CR43","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3899\/jrheum.131003","volume":"41","author":"D van der Heijde","year":"2014","unstructured":"van der Heijde D, Deodhar A, Braun J, et al. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. J Rheumatol. 2014;41(6):1095\u2013103.","journal-title":"J Rheumatol"},{"issue":"1","key":"269_CR44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landewe","year":"2014","unstructured":"Landewe R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73(1):39\u201347.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"269_CR45","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/rheumatology\/keh584","volume":"44","author":"J Braun","year":"2005","unstructured":"Braun J, Baraliakos X, Brandt J, et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford). 2005;44(5):670\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"269_CR46","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1002\/art.39805","volume":"68","author":"AA Deodhar","year":"2016","unstructured":"Deodhar AA, Dougados M, Baeten DL, et al. Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a phase III randomized trial (MEASURE 1). Arthritis Rheumatol. 2016;68(12):2901\u201310.","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-020-00269-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-020-00269-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-020-00269-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T18:05:10Z","timestamp":1628618710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-020-00269-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["269"],"URL":"https:\/\/doi.org\/10.1007\/s40744-020-00269-6","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,22]]},"assertion":[{"value":"29 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}